Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

GlaxoSmithKline targets growth across units, scraps ViiV IPO

May 6 (Reuters) – GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth. It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook. Chief Executive Andrew Witty is under […]

Read More »

Two Under-the-Radar Updates Pfizer (PFE) Investors Need to Know About

Drugmaking behemoth Pfizer Inc. (PFE) had some important information hidden in between the layers Of its first quarter conference call, said a columnist at The Motley Fool on Wednesday, and investors would be wise to take a closer look before parsing out the company’s value. Pfizer had two major updates that could significantly impact its […]

Read More »

8 out of 10 Medical Device Companies Expect Medium or High Levels of Market Competition, According to Recent Survey from Cutting Edge Information

RESEARCH TRIANGLE PARK, NC–(Marketwired – May 05, 2015) – Medical device manufacturers face increasing competition as they move products through development and into a saturated market. According to a new report by primary intelligence provider Cutting Edge Information, 80% of surveyed medical device companies expect medium or high levels of market competition.  Nearly half (49%) of […]

Read More »

Isis Reports Financial Results and Highlights for First Quarter 2015

CARLSBAD, Calif., May 5, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015 compared to a pro forma net operating loss of $22.6 million for the same period in 2014.  Isis’ significantly improved financial results were due to higher […]

Read More »

OPKO Health Acquires EirGen Pharma

MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE:OPK) is pleased to announce the acquisition of EirGen Pharma, Ltd., a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than […]

Read More »

Transparency Is Still A Problem As Big Pharma Struggles With Its Image

“Reputation, built on our past, shapes our present and future. A good reputation can open many doors; a bad reputation can close many more. A good reputation generates respect. A bad reputation breeds suspicion.” Those are not the words of a business consultant or from a television talk show host like Dr. Phil. They are […]

Read More »

IBM’s Watson to guide cancer therapies at 14 centers

  (Reuters) – Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp’s (IBM.N) Watson computer system to choose therapies based on a tumor’s genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients. Oncology is the first specialty where matching therapy to DNA has […]

Read More »

VIVUS Reports First Quarter 2015 Financial Results

MOUNTAIN VIEW, CA–(Marketwired – May 05, 2015) – VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2015. “We have sharpened […]

Read More »

As Hampton Takes Over as Chairman at GlaxoSmithKline (GSK), CEO Witty Needs to Deliver or “Step Aside”

GlaxoSmithKline (GSK) is under scrutiny Tuesday, after more analysts have called for its longstanding chief executive, Sir Andrew Witty, to either step up his performance or resign within the next year, as the company prepares to receive its new chairman later this week. “Mr. Witty is running out of time,” said Stephen Bailey, a fund […]

Read More »

IBM Closes Acquisition of Phytel

ARMONK, N.Y. and DALLAS, May 4, 2015 /PRNewswire/ — IBM (NYSE: IBM) today announced it has completed the acquisition of Phytel, a leading provider of integrated population health management software based in Dallas, Texas. Financial terms of the deal were not disclosed. Phytel is a leader in physician-led population health management software that develops and […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom